S1905 T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if an investigational drug called OBI-3424 is a safe and effective option for patients with leukemia or lymphoma.
Leukemia and Lymphoma
Who Can Participate in the Study?
Adults ages 18+ who have one of the following diagnoses:
- Relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL); OR
- Relapsed or refractory T-cell lymphoblastic lymphoma with lymphoblast greater than 5% in the bone marrow or in the peripheral blood; OR
- Acute leukemia in the peripheral blood or bone marrow with lymphoblasts greater than 5% in the peripheral blood or bone marrow
In addition to the above, all study candidates must also:
- Have no evidence of central nervous system disease within 28 days of joining based on CSF studies
- Have not used chemotherapy or investigational agents within 14 days prior to joining except for steroids, oral 6-mercaptopurine, oral methotrexate,
vincristine, intrathecal chemotherapy, or hydroxyurea - Have not undergone allogeneic hematopoietic transplant within 90 days prior to joining
For more information about who can join this study, please contact the study team at nick.jeffries@duke.edu.
What is Involved?
If you choose to join this study, you will get the study drug, OBI-3424. Different doses of OBI-3424 will be given to several study participants. The first several study participants will receive the lowest dose. If the drug does not cause serious side effects, it will be given to the next several study participants at a higher dose. The doses will continue to increase for every group of study participants until side effects occur that require the dose to be lowered. When the maximum dose is reached, the study will be expanded to additional patients to learn more about that dose.
Study Details
